Everyone has a story to tell, and here we share and celebrate those who chose care as their life's work.
These are their words, their work and we're grateful to share them.
Elizabeth and Dennis handed their billing to Carepatron and grew My Therapeutic Concepts from five clients to seventy in two months, without losing their evenings.
## **What is a gadobutrol injection?**
A gadobutrol injection is a gadolinium-based contrast agent used during magnetic resonance imaging (MRI) that enhances visualization of internal body structures. HCPCS code A9585 represents the injection of gadobutrol in units of 0.1 mL each. This contrast agent improves diagnostic accuracy for conditions involving the blood-brain barrier, tumors, inflammation, and vascular or organ abnormalities.
Unlike standard MRI, which may show limited detail, the use of gadobutrol improves diagnostic accuracy by increasing the visibility of tissues, organs, and lesions throughout the body. It is typically administered intravenously by a doctor or qualified healthcare professional before or during an MRI scan and is carefully dosed based on the patient's weight and clinical need. It helps radiologists and doctors assess conditions affecting the blood-brain barrier, detect tumors, evaluate inflammatory conditions, and examine vascular or organ abnormalities.
Because it plays a crucial role in diagnostic imaging, accurate coding, documentation, and linkage to the MRI service are essential for billing, reimbursement, and compliance with Medicare and Medicaid services.
## **Documentation requirements**
Record should include:
- The contrast agent name, dosage in mL or units, lot number, and expiration date, as per FDA vial labelling.
- The clinical indication for use (e.g., blood-brain barrier disruption, tumor, inflammation)
- The MRI or diagnostic procedure associated with the contra,st including date and provider order
- The time and route of administration (e.g., IV bolus), and any patient reactions or observations.
- The provider signature and credentials, linking the administered contrast to the imaging services.
## **Billing requirements**
Accurate billing for HCPCS code A9585 requires aligning the reported units, modifiers, and revenue codes with Medicare and commercial payer policies
- When billing HCPCS A9585, report one unit for every 0.1 mL of gadobutrol injected, ensuring the total volume is clearly documented in the claim to support reimbursement.
- Modifier JW must be used if drug waste occurs, with discarded units billed separately; modifier JZ should be appended if no drug waste occurred.
- For hospital outpatient claims, report HCPCS A9585 with revenue code 0636 (Drugs requiring detailed coding), consistent with CMS requirements for contrast agent billing. This applies even if the payment is packaged under the Outpatient Prospective Payment System (OPPS).
- In a physician's office or freestanding imaging centers, Medicare typically reimburses A9585 at ASP + 6%, while commercial payers may have their own negotiated rates. In hospital outpatient settings, however, gadobutrol is often packaged into the MRI procedure payment and not separately reimbursed.
- Because rules differ by payer and setting, providers must always confirm whether the contrast is reimbursed separately or bundled into the imaging service.
Each unit of A9585 represents 0.1 mL of gadobutrol. To calculate the billed units, multiply the total volume administered by 10. For example, if a patient receives 6.5 mL, you would bill 65 units. This aligns with the FDA-approved concentration and CMS billing standards.
According to CMS guidelines, use modifier JW when reporting discarded drug amounts from a single-use vial; list the wasted units on a separate claim line. Use modifier JZ when attesting that no residual drug was discarded, as required under CMS and certain payer rules.
Separate billing for A9585 is permitted by many Medicare MACs but may be bundled by some commercial payers into the global MRI procedure. Always confirm individual payer policies for reimbursement, required modifiers, and prior authorization rules to avoid denials.
